Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Desflurane
Drug ID BADD_D00611
Description Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.[L30285]
Indications and Usage Desflurane is indicated for the induction and maintenance of anesthesia in adults, as well as the maintenance of anesthesia in pediatric patients.[L30285]
Marketing Status approved
ATC Code N01AB07
DrugBank ID DB01189
KEGG ID D00546
MeSH ID D000077335
PubChem ID 42113
TTD Drug ID D0H4GN
NDC Product Code 0404-9961; 52584-641; 66794-021; 0781-6172; 10019-641; 57884-0028; 10019-644; 10019-646
UNII CRS35BZ94Q
Synonyms Desflurane | 1,2,2,2-Tetrafluoroethyl difluoromethyl ether | I 653 | I-653 | I653 | Suprane
Chemical Information
Molecular Formula C3H2F6O
CAS Registry Number 57041-67-5
SMILES C(C(F)(F)F)(OC(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cyanosis02.11.04.004; 22.02.02.007; 23.06.04.005; 24.03.01.007--
Discomfort08.01.08.003---
Dizziness02.11.04.006; 17.02.05.003; 24.06.02.0070.001215%
Dyspnoea02.11.05.003; 22.02.01.004--
Electrocardiogram abnormal13.14.05.001---
Electrocardiogram T wave inversion13.14.05.007---
Encephalopathy17.13.02.001--
Endophthalmitis06.04.05.009; 11.01.06.003--
Erythema23.03.06.0010.000179%-
Extrasystoles02.03.02.003---
Eye disorder06.08.03.001---
Eye irritation06.04.05.0030.000268%-
Eye pain06.08.03.002--
Fatigue08.01.01.002--
Feeling abnormal08.01.09.014---
Gastrointestinal disorder07.11.01.001---
Gastrointestinal pain07.01.05.005--
Haemoglobin13.01.05.018---
Haemoptysis02.11.04.009; 22.02.03.004; 24.07.01.006---
Headache17.14.01.001--
Hepatic failure09.01.03.002--
Hepatic function abnormal09.01.02.001---
Hepatic necrosis09.01.07.002--
Hepatitis09.01.07.0040.000447%-
Hepatocellular injury09.01.07.008---
Hypercapnia14.01.04.001; 22.02.02.0020.000179%-
Hyperkalaemia14.05.03.001--
Hypertension24.08.02.001--
Hyperthermia malignant08.05.01.0020.001018%-
Hypervolaemia02.05.04.019; 14.05.06.003---
The 2th Page    First    Pre   2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene